SEGMENT INFORMATION - Schedule of Reconciliation to the consolidated net loss (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Revenue:
Total revenue	$ 40,785	$ 31,837
Costs and operating expenses:
Total costs and operating expenses	176,550	185,444
Loss from operations	(135,765)	(153,607)
Other income (expense):
Interest income	7,986	7,779
Other income (expense), net	256	(584)
Benefit from income taxes	34,336	40,199
Net loss	(93,187)	(106,213)
Depreciation	4,210	4,695
Reportable Segment
Revenue:
Total revenue	40,785	31,837
Costs and operating expenses:
Compensation	62,775	63,760
Depreciation and intangible assets amortization	37,222	37,679
Stock-based compensation	16,260	15,449
Professional Services	10,149	9,195
Cloud computing and information technology	6,480	6,743
Clinical Studies	5,944	5,922
Facilities	5,248	5,631
Laboratory supplies and research collaborations	1,420	3,667
Other segment expenses	9,432	19,104
Total costs and operating expenses	176,550	185,444
Loss from operations	(135,765)	(153,607)
Other income (expense):
Interest income	7,986	7,779
Other income (expense), net	256	(584)
Benefit from income taxes	34,336	40,199
Net loss	(93,187)	(106,213)
Depreciation	500	800
Screening revenue
Revenue:
Total revenue	39,832	29,133
Costs and operating expenses:
Cost of revenue	21,244	17,123
Screening revenue | Reportable Segment
Revenue:
Total revenue	39,832	29,133
Costs and operating expenses:
Cost of revenue	21,244	17,123
Development services revenue
Revenue:
Total revenue	953	2,704
Costs and operating expenses:
Cost of revenue	376	1,171
Development services revenue | Reportable Segment
Revenue:
Total revenue	953	2,704
Costs and operating expenses:
Cost of revenue	$ 376	$ 1,171